<DOC>
	<DOCNO>NCT00004043</DOCNO>
	<brief_summary>RATIONALE : Calcitriol , form vitamin D , may able prevent slow growth prostate cancer cell . PURPOSE : Phase II trial study effectiveness calcitriol treat patient rise PSA level follow previous treatment prostate cancer .</brief_summary>
	<brief_title>Calcitriol Treating Patients With Rising PSA Level Following Treatment Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response pulse calcitriol patient previously treat adenocarcinoma prostate rise PSA level . II . Assess impact regimen slope PSA rise patient . III . Determine qualitative quantitative toxic effect regimen patient . IV . Assess impact regimen quality life patient . OUTLINE : All patient remain reduced calcium diet duration study . Twelve hour prior treatment , patient begin drink 4-6 glass extra fluid 3 day . Patients receive oral calcitriol 4 hour weekly . Treatment continue absence disease progression unacceptable toxicity . Quality life assess baseline , every 4 week treatment , end study . Patients follow least 1 month . PROJECTED ACCRUAL : A total 15-25 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven adenocarcinoma prostate previously treat prostatectomy definitive radiotherapy Rising PSA post definitive therapy nadir least 3 measurement least 2 week apart PSA least 0.4 ng/mL prostatectomy patient PSA least 1.0 ng/mL radiotherapy patient PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Phosphate great 4.2 mg/dL Creatinine great 1.3 mg/dL Calcium great 10.5 mg/dL No history hypercalcemia Cardiovascular : No significant heart disease No myocardial infarction within past 3 month No history heart failure Cardiac ejection fraction least 30 % Other : No significant active medical illness would preclude compliance Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy metastatic prostate cancer ( except neoadjuvant treatment localized prostate cancer ) Endocrine therapy : No prior systemic hormonal therapy prostate cancer ( except neoadjuvant treatment localized prostate cancer ) Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent systemic therapy metastatic prostate cancer At least 30 day since prior investigational drug No concurrent digoxin At least 7 day since prior thiazide diuretic therapy No concurrent magnesium contain antacid , bile resin binding drug , calcium supplement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>